USANA Health Sciences Inc (USNA)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 181,768 | 330,420 | 288,420 | 239,832 | 311,917 |
| Short-term investments | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 139,625 | 118,845 | 143,833 | 160,790 | 168,073 |
| Cash ratio | 1.30 | 2.78 | 2.01 | 1.49 | 1.86 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($181,768K
+ $—K)
÷ $139,625K
= 1.30
The cash ratio of USANA Health Sciences Inc has shown fluctuations over the past five years. As of December 31, 2020, the cash ratio was 1.86, indicating that the company had $1.86 in cash and cash equivalents for every dollar of current liabilities. By December 31, 2021, the cash ratio decreased to 1.49, suggesting a slight liquidity decline.
However, the company's liquidity position improved significantly by December 31, 2022, with a cash ratio of 2.01, reflecting a healthier ability to cover short-term obligations. This positive trend continued in 2023, as the cash ratio further increased to 2.78, indicating a robust liquidity position.
Unfortunately, by December 31, 2024, the cash ratio dropped to 1.30, which might raise concerns about USANA Health Sciences Inc's ability to meet its short-term obligations with its available cash reserves. Monitoring the cash ratio closely can provide insight into the company's liquidity management and financial health over time.